



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 11-05-2026

To,
DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street,
Mumbai- 400001

Scrip Code: 524606

ISIN: INE415H01017


Sub: Disclosure under Regulation 30 read with Regulation 23 of SEBI (LODR) Regulations, 2015 – Approval of Material Related Party Transaction with M/s. Aminova Infusions Pvt. Ltd.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholders of the Company at the Extra-Ordinary General Meeting held on 11th May, 2026 at 11:00 A.M. Concluded at 11:30 A.M. at Kanchan Palace, Community Hall, Nipania Ring Road, Indore- 452001 have approved the Material Related Party Transaction(s) with Aminova Infusions Pvt Ltd.

The details of the transaction are as under:

| Particulars | Details |
|------------------------|--|
| Name of Related Party | Aminova Infusions Pvt Ltd |
| Nature of Relationship | Mr. Shailendra Pathak, a WTD of the Company is the Promoter of Aminova. |
| Nature of Transaction | Distribution of Company's products in other market like Maharashtra, Gujrat etc |
| Monetary Value | Rs. 5 Cr |
| Duration | 2 years starting from 3rd January 2026 ending on 2nd January 2028. |
| Material Terms | <p>i) The prices would be based on the market rates and would be ex-factory. (i) Payment as per market terms. (iii) The Company shall not be responsible for any breakage once the goods are handed over to Aminova but would replace the products in case of leakage on receipt of empty bottles with seal intact. (iv) The supplies would be subject to availability of stock. (v) The rates are subject to revision without prior intimation. (vi) Taxes would be charged extra at applicable rates. (vii) The transaction between the Company and Aminova would be subject to Indore jurisdiction only. (viii) In the event of any claim, difference or dispute, between the Company and Aminova, the matter shall be referred to a Sole arbitrator, Mr. Ritesh Jain for adjudication and the arbitration shall be conducted at Indore, subject to the provisions of the Arbitration and Conciliation Act, 1996.</p> |




The said transaction(s) shall be undertaken on an arm's length basis and in the ordinary course of business, wherever applicable.

Kindly take the same on record.

Thanking You,

For Beryl Drugs Limited

1052
Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

THE CERTIFIED TRUE COPY OF THE RESOLUTIONS PASSED AT THE EXTRA-ORDINARY GENERAL MEETING OF THE BERYL DRUGS LIMITED HELD ON MONDAY, THE 11th DAY OF MAY, 2026 AT 11.00 A.M. AT KANCHAN PALACE, COMMUNITY HALL, NIPANIA RING ROAD INDORE (M.P.)

"RESOLVED THAT pursuant to the applicable provisions of the Companies Act, 2013 ("Act") read with the applicable Rules made thereunder (including any statutory modification(s) or re-enactment thereof, for the time being in force), Provisions of Regulation 23 and other applicable provisions of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time, the Company's policy on "Materiality of Related Party Transactions and also on dealing with Related Party Transactions", all other applicable laws and regulations, as amended, supplemented or re-enacted from time to time, subject to such other approvals, consents, permissions and sanctions of other authorities as may be necessary and pursuant to, the consent of the Audit Committee and the Board of Directors of the Company, the approval of the Members of the Company be and is hereby accorded to for entering into and / or carrying out and / or continuing with existing contracts / arrangements/ transactions or modification(s) of earlier/ arrangements/ transactions or as fresh and independent transaction(s) or otherwise (whether individually or series of transaction(s) taken together or otherwise), with M/s. Aminova Infusions P. Ltd., a related party of the Company, as per the details set out in the Explanatory Statement annexed to this notice, notwithstanding the fact that the aggregate value of all these transaction(s), whether undertaken directly by the Company or alongwith its subsidiary(ies), may exceed the prescribed thresholds as per provisions of the SEBI Listing Regulations as applicable from time to time, provided, however, that the said contract(s)/ arrangement(s)/ transaction(s) shall be carried out at an arm's length basis and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board of Directors (hereinafter referred to as the "Board" which term shall be deemed to include any Committee thereof) be and are hereby authorized to perform and execute all such deeds, matters and things including delegation of authority as may be deemed necessary or expedient to give effect to this resolution and for the matters connected therewith or incidental thereto".

// CERTIFIED TRUE COPY //

For Beryl Drugs Limited

Sudhir Sethi
Chairman & Director
DIN NO: 00090172



EXPLANATORY STATEMENT

Mr. Shailendra Pathak, the promoter and majority shareholder of Aminova has been appointed as a WTD by a resolution of the Board of Directors dated 3rd January 2026, therefore Aminova is a related party in accordance with the provisions of Section 2(76) of the Companies Act, 2013.

The provisions of the SEBI Listing Regulations, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Sixth Amendment) Regulations, 2021, effective April 1, 2022, mandates prior approval of members by means of an ordinary resolution for all material related party transactions and subsequent material modifications as defined by the Audit Committee, even if such transactions are in the ordinary course of business of the concerned company and at an arm's length basis. Effective from April 1, 2022, a transaction with a Related Party shall be considered as material if the transaction(s) to be entered into, either individually or taken together with previous transactions during a financial year, whether directly and/or through its subsidiary(ies), exceed(s) ₹ 1,000 crore, or 10% of the annual consolidated turnover as per the last audited financial statements of the listed entity, whichever is lower.

The Company proposes to enter into certain Related Party Transaction(s) as mentioned below, on mutually agreed terms and conditions, and the aggregate of such transaction(s), are expected to cross the applicable materiality thresholds as mentioned above. Accordingly, as per the SEBI Listing Regulations, prior approval of the Members is being sought for all such arrangements / transactions proposed to be undertaken by the Company. All the said transactions shall be in the ordinary course of business of the Company and on an arm's length basis. The Audit Committee has, on the basis of relevant details provided by the management, as required by the law, at its meeting held on 3rd January, reviewed and approved the said transaction(s), subject to approval of the Members, while noting that such transaction shall be on arms' length basis and in the ordinary course of business of the Company. Your Board of Directors considered the same and recommend the passing of the resolutions contained in Item No. 3 of this Notice.

Background and Details of the Proposed Transaction:

The company is in the production of PP Bottle and FFS products, as detailed under point 3 below and supplying to various government and non-government organisations. The company is selling the products directly and also through the vendors. Aminova, a company promoted by Mr. Shailendra Pathak has proposed to distribute the company's products in other markets like Maharashtra and Gujrat Etc. and also exporting to other countries. Based on the knowledge and expertise of Mr. Shailendra Pathak, the company has decided to enter into an agreement with Aminova dated 3rd January 2026 defining therein the terms and conditions. The said transaction is at arms' length as the company is selling the products to other vendors on the same terms and conditions.




Information required under Regulation 23 of SEBI Listing Regulations read with SEBI Circular dated 13th October 2025 is provided herein below:

Material Related Party Transactions by the Company Resolution Item No. 3:

Particulars of material related party transactions between Beryl Drugs Limited and M/s. Aminova Infusions Pvt. Ltd.

| S. No. | Particulars | Details |
|--------|--|---|
| 1. | Name of the related party | M/s. Aminova Infusions Pvt. Ltd. |
| 2. | Nature of relationship with the company | Mr. Shailendra Pathak, a WTD of the Company is the Promoter of Aminova. |
| 2. | Type, tenure, material terms and particulars of the proposed transaction. | As per Annexure 2 |
| 3. | Value of the transaction | Rs. 5 cr. |
| 4. | The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction (and for a RPT involving a subsidiary, such percentage calculated on the basis of the subsidiary's annual turnover on a standalone basis shall be additionally provided). | Approx 13.30% |
| 5. | If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary: | Not Applicable |
| (i) | details of the source of funds in connection with the proposed transaction; | Not Applicable |
| (ii) | where any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments, <ul style="list-style-type: none"> • nature of indebtedness; • cost of funds; and • tenure; | Not Applicable |
| (iii) | applicable terms, including | Not Applicable |



| | | |
|------|--|---|
| | covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security; and | |
| (iv) | the purpose for which the funds will be utilised by the ultimate beneficiary of such funds pursuant to the RPT. | Not Applicable |
| 6. | Justification as to why the RPT is in the interest of the listed entity. | Mr. Shailendra Pathak is a veteran in the pharmaceutical field with exposure to other markets including foreign markets. This RPT will help the company to access large market segment which may multi-fold company's turnover and also the profits. |
| 7. | Any valuation or other external report relied upon by the listed entity in relation to the transactions. | Not Applicable |
| 8. | Any other information that may be relevant or important to the shareholders to take an informed decision. | The promoters of the company know Mr. Shailendra Pathak since the last 10-15 years and taking his opinion in certain matters. The RPT will enable the company to utilise his full knowledge and expertise of the products and his exposure to the market. |

